EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia

Tianli Liu, Xiaoling Cheng, Yupeng Wang, Wenli Hao, Hangyu Wang, Ke Zhang iD, Jinhui Wang iD

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Tianli Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, DNA-Directed RNA Polymerases, Drug Design, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Regional Joint Fund of National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The metabolic dependence of acute myeloid leukemia (AML) cells on mitochondrial oxidative phosphorylation (OXPHOS) has become a cutting‐edge area in cancer energy metabolism research, playing a pivotal role in cell survival and drug resistance. Consequently, targeted inhibition of human mitochondrial RNA polymerase (POLRMT) to block mitochondrial gene expression emerges as a novel potential strategy for treating AML through OXPHOS modulation. In this study, based on the previously reported crystal structure of the POLRMT inhibitor IMT1B, we employed a scaffold hopping strategy to design and synthesize a series of derivatives featuring additional hydrophobic occupying groups. A new potent POLRMT inhibitor ( 10a ) was discovered, which displayed potent antiproliferative activity and could disrupt mitochondrial function and induce apoptosis in MOLM‐13 cells. Together, these results demonstrate that 10a is a new POLRMT inhibitor, which may provide a candidate lead for AML treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDNA-Directed RNA PolymerasesDrug DesignEnzyme InhibitorsLeukemia, Myeloid, AcuteHumansApoptosisCell Line, TumorCell ProliferationMitochondriaMolecular Docking SimulationOxidative PhosphorylationStructure-Activity Relationship

Stichwörter der Autor:innen

AMLOXPHOSPOLRMT inhibitor

Substanzen

Antineoplastic AgentsDNA-Directed RNA PolymerasesEnzyme InhibitorsPOLRMT protein, human

Autor:innen und Institutionen

  • Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, China.

ORCID-Profile: Ke Zhang, Jinhui Wang

Förderung

  • Regional Joint Fund of National Natural Science Foundation of China

Zitieren

APA

Liu, T., Cheng, X., Wang, Y., Hao, W., Wang, H., Zhang, K., & Wang, J. (2025). Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70127

Vancouver

Liu T, Cheng X, Wang Y, Hao W, Wang H, Zhang K, et al. Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70127

BibTeX
@article{Liu2025,
  author = {Liu, Tianli and Cheng, Xiaoling and Wang, Yupeng and Hao, Wenli and Wang, Hangyu and Zhang, Ke and Wang, Jinhui},
  title = {Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70127}
}
Kostenlos starten →